Condition
Inflammaging
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Not Yet Recruiting2
Terminated1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07614542Recruiting
AGEWISE: Unravelling the Gut-Hormone Axis in Women's Ageing
NCT07395921Not ApplicableNot Yet Recruiting
Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.
NCT07372417Not Yet Recruiting
Macrophage/Monocyte Driven Inflammation and Anesthetic Sensitivity in Aging
NCT04983017Not ApplicableTerminated
2021 PMT iAge® Intervention Trial by Edifice Health
NCT03308747Not ApplicableCompletedPrimary
Inflammaging and Muscle Protein Metabolism
Showing all 5 trials